ImmunityBio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 628
- Market Cap
- $2.9B
- Website
- http://www.immunitybio.com
- Introduction
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong ...
This Biotech Stock Could Rocket 800%, Analyst Says
EF Hutton analyst Jason Kolbert initiated coverage of ImmunityBio with a Buy rating and a $30 price target, implying a 767% upside. ImmunityBio's Anktiva, approved by the FDA for non-muscle invasive bladder cancer, activates the immune system to eliminate tumor cells and convert cold tumors into hot ones, potentially improving outcomes in various cancers.
Genenta's CEO to present at the U.S. Senate meeting on Cross-Border Investments and Strategies in the Biotechnology Sector
Genenta Science's CEO, Pierluigi Paracchi, to speak at 'Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective' on Oct 25 at U.S. Senate, organized by NSCEB and Italian Embassy in the U.S.
Genenta's CEO to present at the U.S. Senate meeting on Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective
Genenta Science's CEO, Pierluigi Paracchi, to speak at 'Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective' on Oct 25, 2024, in Washington, D.C., discussing biotech sector internationalization and strategic investments.
Genenta's CEO to present at the U.S. Senate meeting on
Genenta Science's CEO, Pierluigi Paracchi, to speak at the Italy-U.S. meeting on biotechnology strategies on October 25, 2024, in Washington, D.C., discussing the importance of international collaboration and investment in biotech.
© Copyright 2024. All Rights Reserved by MedPath